• Sarcoma: Targeting Treatment by Activating Pathways
  • CME

  • Sarcoma: Targeting Treatment by Activating Pathways

  • Author(s)/Faculty: Sant P. Chawla, MD; Monica Mita, MD; Scott H. Okuno, MD; Andrew J. Wagner, MD, PhD
    Source: HemOnc Today
    Type: Monograph Articles/Items: 1
    Release Date: 12/10/2011 Expiration Date: 12/10/2012
    Credit Type: CME Number of Credit(s): 1.25
    Cost: Free Provider: Vindico Medical Education

  • Limited treatment options are available for metastatic sarcoma. This monograph will review inhibition of the mTOR pathway, a promising therapeutic rationale currently in development for the management of this devastating disease. Preliminary results of a recent clinical trial of an mTOR inhibitor will be presented, highlighting the efficacy and safety of this treatment approach.

Sponsorship Statement: This continuing medical education activity is jointly sponsored by Vindico Medical Education and HemOnc Today

Support Statement: This activity is supported by an educational grant from

Target Audience:
The intended audience for the activities is medical oncologists, surgical oncologists, hematologists, oncology nurses, and other health care professionals involved in the treatment of patients with sarcoma.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Discuss the limitations of current treatment options for advanced or metastatic sarcoma.
  • Describe the known pathways that can be used as potential targets in the treatment of sarcoma.
  • Evaluate the clinical efficacy and toxicity of investigational agents that target signaling pathways to treat sarcoma.

Course Chair:
Scott H. Okuno, MD
Professor of Oncology
Mayo Clinic
Rochester, MN

Faculty:
Sant P. Chawla, MD
Director of Medical Oncology, UCLA-Santa Monica Hospital
Director of Medical Oncology at Orthopaedic Hospital
Director of Medical Oncology at Century City Hospital
Director, Sarcoma Oncology Center
Santa Monica, CA

Monica Mita, MD
Co-Director, Experimental Therapeutics Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Andrew J. Wagner, MD, PhD
Assistant Professor, Department of Medicine
Harvard Medical School
Dana Farber Cancer Institute
Boston, MA

Accreditation:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vindico Medical Education and HEMONC TODAY®. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For the purpose of recertifying with the American Nurses Credentialing Center, AMA PRA Category 1 CME Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education can be used.

This enduring material is approved for 1 year from the date of original release, December 10, 2011 to December 10, 2012.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate.

Planning Committee and Faculty:
Sant P. Chawla, MD
Monica Mita, MD
Scott H. Okuno, MD
Andrew J. Wagner, MD, PhD

External Reviewer:
Keith Skubitz, MD

Medical Writer:
Bruce Wilson

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):
Sant P. Chawla, MD
Consulting Fees: Amgen, Sanofi-aventis, Threshold Pharmaceuticals, Merck & Co

Monica Mita, MD
 No relevant financial relationships to disclose.

Scott H. Okuno, MD
No relevant financial relationships to disclose.

Andrew J. Wagner, MD, Phd
Consulting Fees: Novartis, EMD Serono, Pfizer

External Reviewer reports the following relationship(s):
Keith Skubitz, MD
Royalty: U of Minnesota for antibody
Receipt of Intellectual Property Rights/Patent Holder: Patent for mucositis Rx — not licensed; no income
Consulting Fees: Seattle Genetic consultant
Contracted Research (Clinical trials): Amgen, Ariad/Merck, Bayer, GlaxoSmithKline, Imclone, Infinity, Pfizer, Schering
PloughOwnership Interest: Publicly traded stock in Johnsn & Johnson
Other: Expert witness re: osteonecrosis of the jaw with bisphosphonates

Medical Writer reports the following relationship(s):
Bruce Wilson
No relevant financial relationships to disclose.

Vindico Medical Education and HEMONC TODAY® staff report the following relationship(s):
 No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2011 SLACK Incorporated®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and HEMONC TODAY® continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and HEMONC TODAY®. Neither Vindico Medical Education, HEMONC TODAY®, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.